Artificial oncolytic viruses and related methods
AssigneeHumane Genomics
InventorsChad M. Moles, Peter E. Weijmarshausen
Life of this patent
Estimating the term…
Abstract
The disclosure provides artificial viral compositions for use in treating cancer or a hyperproliferative disorder in a subject to whom the compositions are administered, as well as to methods of making and using the compositions.
Claims48
An artificial oncolytic virus comprising a domain engineered to selectively bind to a target cell via a binding partner identified as highly expressed or preferentially expressed on the target cell as compared with a non-target cell.
An artificial oncolytic virus wherein expression of the viral genome is engineered to be under the control of a regulatory region of a gene identified as highly expressed or preferentially expressed by the target cell as compared with a non-target cell.
An artificial oncolytic virus comprising a sequence of SEQ ID NO:
- 2.
A pharmaceutical composition comprising an artificial oncolytic virus comprising a domain engineered to selectively bind to a target cell via a binding partner identified as highly expressed or preferentially expressed on the target cell as compared with a non-target cell.
A method of treating a hyperproliferative disorder in a subject comprising administering to the subject a pharmaceutical composition comprising an effective amount of an artificial oncolytic virus comprising a domain engineered to selectively bind to a target cell via a binding partner identified as highly expressed or preferentially expressed on the target cell as compared with a non-target cell.
A method of slowing, inhibiting or reducing the growth or size of a tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of an artificial oncolytic virus comprising a domain engineered to selectively bind to a target cell via a binding partner identified as highly expressed or preferentially expressed on the target cell as compared with a non-target cell.
A method of producing an artificial oncolytic virus comprising:
- (a) designing the DNA for said virus to produce viral DNA, wherein the DNA comprises a domain engineered to selectively bind to a target cell via a binding partner identified as highly expressed or preferentially expressed on the target cell as compared with a non-target cell;
- (b) defining fragments of the viral DNA for synthesis;
- (c) synthesizing the viral DNA fragments;
- (d) assembling the viral DNA fragments to create artificial oncolytic viral DNA;
- and (e) transfecting cells with said artificial oncolytic viral DNA to produce artificial oncolytic virus.
Dependencies are inferred from the claim text.